

# report



meeting	<b>HEALTH SELECT COMMITTEE</b>	
date	<b>2 May 2006</b>	<b>agenda item number</b>

## **Report of the Chair of the Health Select Committee**

## **National Institute for Clinical Excellence (NICE)**

### **Purpose of the report**

1. To provide the Health Select Committee with an opportunity to consider information requested on the relationship of the National Institute for Clinical Excellence (NICE) with primary healthcare in Nottinghamshire.

### **Background**

2. NICE is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.
3. Currently NICE produces guidance in three areas of health:
  - Technology appraisals - guidance on the use of new and existing medicines and treatments within the NHS in England and Wales.
  - Clinical guidelines - guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS in England and Wales.
  - Interventional procedures - guidance on whether interventional procedures used for diagnosis or treatment are safe enough and work well enough for routine use in England, Wales and Scotland.
4. Dr Mary Corcoran, Director of Public Health, Gedling Primary Care Trust (PCT) is the lead for Broxtowe & Hucknall, Gedling, Nottingham City and Rushcliffe PCTs attended the meeting on 21 March 2006 to provide information to the Select Committee.

### **Issues**

5. Dr Corcoran offered to provide a paper that was being considered by Gedling PCT. The paper was approved by the Board of Gedling PCT on

21 March 2006 and is attached at Appendix 1 for Members' consideration.

6. The paper sets out the process followed by Broxtowe & Hucknall, Gedling, Nottingham City and Rushcliffe PCTs in introducing new technologies and pharmaceutical products.
7. At the meeting on 21 March 2006, Members of the Select Committee identified that the processes for introducing new technologies and pharmaceutical products appeared to vary with each PCT.
8. Newly licensed drugs are reviewed for the four Greater Nottingham PCTs by the Area Prescribing Committee. Information is being sought as to the membership of this Committee and to identify the involvement of Acute trusts in these processes.
9. Guidance on the introduction of new technologies and pharmaceutical products for cancer would appear to vary across the County as it is covered by two cancer networks.

### **Options**

10. The Select Committee may wish to make recommendations that NHS Trusts in Nottinghamshire develop a joint approach to the introduction of new technologies and pharmaceutical products.
11. The Select Committee may wish to consider the information provided and identify issues that require further consideration.

### **Recommendations**

12. It is recommended that

The Health Select Committee consider the information provided and identifies any issues that require further consideration.

**Councillor James T Napier**  
**Chair, Health Select Committee**

Background papers: nil.